In a boost for Merck (MRK), the U.S. Supreme Court tossed a lower-court ruling that had revived more than 500 lawsuits accusing the drug maker of failing to properly warn patients about thigh-bone fractures traced to its widely used Fosamax treatment for osteoporosis.

The justices want a federal appeals court to reconsider its 2018 ruling that allowed the lawsuits to proceed. Merck has argued that it tried to update warnings on the product labeling, but that the Food and Drug Administration rejected its efforts over disagreements with proposed wording about fracture risks. Last summer, the U.S. Solicitor General had urged the Supreme Court to review the case.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy